Premenstrual syndrome

Minerva Ginecologica

Volumn 54, Issue 2, 2002, Pages 85-95

  Gianetto Berruti, A ^a   Feyles, V ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LHSC University Campus   (Canada)

Author keywords

Premenstrual syndrome, prevention and control; Premenstrual syndrome, therapy; Premestrual syndrome, diagnosis

Indexed keywords

ALPHA TOCOPHEROL; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CALCIUM CARBONATE; CITALOPRAM; DANAZOL; DIAZEPAM; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; GESTAGEN; GONADORELIN DERIVATIVE; HERBACEOUS AGENT; MAGNESIUM; MINERAL; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PRIMROSE OIL; PROGESTERONE; PYRIDOXINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN; VITEX AGNUS CASTUS EXTRACT;

AFFECT; CLINICAL FEATURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG INDUCED DISEASE; EXERCISE; HUMAN; LEISURE; META ANALYSIS; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; VITEX AGNUS CASTUS;

ALDOSTERONE ANTAGONISTS; ANTI-ANXIETY AGENTS; CLINICAL TRIALS; CONTRACEPTIVES, ORAL; DANAZOL; DIAGNOSIS, DIFFERENTIAL; DIET; DIURETICS; ESTROGEN ANTAGONISTS; EXERCISE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LIFE STYLE; MINERALS; PLANT PREPARATIONS; PREMENSTRUAL SYNDROME; PROGESTINS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH; SEROTONIN UPTAKE INHIBITORS; SPIRONOLACTONE; VITAMINS;

EID: 0036083454     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Clinical trials of treatment of premenstrual syndrome: Entry criteria and scales for measuring treatment outcomes
2. Evaluating and managing premenstrual syndrome
3. Premenstrual syndrome-pathophysiologic cosiderations. Editorials
4. Premenstrual syndrome
5. Incidence of premenstrual syndrome in twins
6. Genetics and environmental variation in two British twins samples
7. Fluoxetine in the treatment of premenstrual dysphoria
8. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder
9. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms
10. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progesteron postmenopausal replacement therapy
11. Premenstrual syndrome
12. Neurosteroids and behaviour
13. Luteal-phase estradiol relates to symptoms severity in patients with premenstrual syndrome
14. Differences in cortisol, a stress hormone, in women with turmoil-type premenstrual symptoms
15. Luteal phase ovarian steroids, stress arousal, premenses perceived stress, and premenstrual symptoms
16. Sex steroid hormones modulate serum ionized magnesium and calcium throughout the menstrual cycle
17. Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms
18. Magnesium supplementation alleviates premenstrual symptoms of fluid retention
19. Peripheral measures of arginine vasopressin, atrial natriuretic peptide and adrenocorticotropic hormone in premenstrual syndrome
20. Prolactin response to thyrotropin-releasing hormone as a guidline for cyclical mastalgia treatment
21. Diet and sex-hormone binding globulin, dysmemorrhea, and premenstrual symptoms
22. Influence of menstrual factors and dietary habits on menstrual pain in adolescent age
23. Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women
24. The effect of exercise on depression, anxiety, and other mood states: A review
25. Complementary/alternative therapies for premenstrual syndrome: A systematic review of randomized controlled trials
26. Pyridoxine (vitamin B6) and the premenstrual syndrome: A randomized crossover trial
27. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: Systematic review
28. Antioxidant mobilization in response to oxidative stress: A dynamic environmental-nutritional interactions
29. The effect of α-tocopherol on premenstrual symptomatology: A double blind study
30. Efficacy of α-tocopherol on premenstrual syndrome
31. Trends in alternative medicine use in the United States, 1990-1997
32. A survey of 685 women who report symptoms of premenstrual syndrome
33. Incidence of premenstrual syndrome and remedy usage: A national probability sample study
34. The chaste tree: Vitex agnus castus
35. Agnus castus
36. Vitex agnus castus L.: (1) A review of its traditional and modern therapeutic use; (2) current use from a survey of practitioners
37. Agnus castus extract inhibit prolactin secretion of rat pituitary cells
38. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: Direct evidence for a dopaminergic principle by the dopamine receptor assay
39. The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects)
40. Pharmacological activities of Vitex agnus castus in vitro
41. Chaste tree fruit
42. A double-blind clinical trial on a herbal remedy for premenstrual syndrome: A case study
43. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double blind study versus pyridoxine
44. Treatment of the premenstrual syndrome with agnus castus fruit extract: Prospective, randomized, placebo controlled study
45. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus
46. Evening primrose oil
47. Abnormal essential fatty acids level in plasma of women with premenstrual syndrome
48. Is evening primrose oil of value in the treatment of premenstrual syndrome?
49. The serotonin transporter: A primary target for antidepressant drugs
50. The role of monoamines in suicidal behaviour
51. Migraine and depression: Biological aspects
52. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder
53. Antidepressant update
54. Rational drug use in the treatment of depression
55. The role of central seronergic dysfunction in the etiology of premenstrual dysphoric disorder: Therapeutic implications
56. Role of estrogen in the etiology and treatment of mood disorders
57. Sertraline in the treatment of premenstrual dysphoric disorder
58. Contemporary management of depression
59. The serotonin syndrome
60. Drugs interactions with selective serotonin reuptake inhibitors, especially with other psychotropics
61. Sistematic review and guide to selection of selective reuptake inhibitors
62. Fluvoxamine in the treatment of menstrually related mood disorders
63. Fluoxetine treatment of severe premenstrual syndrome
64. Pharmachologic treatments for premenstrual dysphoric disorders
65. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome
66. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phase more effective than continuous medication throughout the menstrual cycle?
67. Fluoxetine in the treatment of late luteal phase dysphoric disorder
68. Depression and anxiety disorders
69. Reduction in the occipital cortex GABA levels in panic disorders detected with H-magnetic resonance spectroscopy
70. Benzodiazepines as antidepressants: Does GABA play a role in depression?
71. Type A γ-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: Significanse to clinical syndromes and their treatment
72. Pharmacotherapy of generalized anxiety disorder
73. Treatment of premenstrual dysphoria with alprazolam. A controlled study
74. A double blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome
75. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: A comparison of buspirone, nefazodone and placebo
76. Induced anovulation as a treatment of premenstrual tension syndrome: A double blind cross-over study with GnRH-agonist versus placebo
77. Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial
78. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome
79. Differential behavioral effect of gonadal steroids in women with and in those without premenstrual syndrome
80. The treatment of severe premenstrual syndrome with goserelin with and without "add-back" estrogen therapy: A placebo-controlled study
81. Premenstrual tension
82. Progesterone and the premenstrual syndrome: A double blind crossover trial
83. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome
84. A double-blind trial of progesterone, alprazolam and placebo in the treatment of severe premenstrual syndrome
85. Efficacy of progesterone and progestogens in management of premenstrual syndrome: Systematic review
86. Hormonal therapy in the management of premenstrual syndrome
87. Danazol. A synthetic steroid with diverse biologic effects
88. A randomized, placebo-controlled crossover trial of danazol for the treatment of premenstrual syndrome
89. Elimination of ovulation and menstrual cyclicity with danazol improves dysphoric premenstrual syndromes
90. Mastalgia: A 3-year Australian study
91. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol
92. Treatment of premenstrual syndrome by spironolactone
93. Effect of spironolactone on premenstrual syndrome symptoms
94. Spironolactone in the treatment of premenstrual tension: A double-blind study of spironolactone versus bendroflumethiazide and placebo
95. Premenstrual tension: A placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate
96. Treatment of premenstrual syndrome by spironolactone: A double blind, placebo controlled study
97. Changes in psychological symptoms in women taking oral contraceptives
98. Types of oral contraceptives, depression and premenstrual syndrome
99. The influence of method of contraception and cigarette smoking on menstrual patterns
100. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use
101. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms
102. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive
103. Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations
104. Relationship between premenstrual symptoms and oral contraceptive use: A controlled study
105. The novel progestin drospirenone and its natural counterpart progesterone. Biochemical profile and antiandrogen potential
106. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity
107. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder